ArticleActa pharmaceutica Sinica. B2025
Generation and applications of an expandable and mature hiPSC-derived liver organoid.
Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organoids have emerged as a powerful tool for modeling liver diseases, drug screening, and personalized treatments. However, they have a limited capacity to generate functional hepatocytes in a reproducible and efficient manner. Here, we designed a novel method to efficiently and reproducibly establish a protocol for generating functionally mature SB-HEOs (SB431542/BMP4-hepatic endoderm organoids) from hiPSC-derived hepatic endoderm (HE) cells. The maturation of these organoids was confirmed through transcriptome analysis and functional expression detection. We extended this culture system to various biomedical applications. This system can be used to identify hepatotoxicity with DILI drugs, model disease using OA stress, metabolize drugs using liquid chromatography-tandem mass spectrometry, and repopulate FRG mice. These organoids have both expansion and maturation characteristics, high drug metabolism ability to prolong the survival of FRG mice, can accurately identify hepatotoxic and non-hepatotoxic drugs, and mimic metabolic dysfunction-associated steatotic liver disease. Thus, SB
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.